Making the case for EGFR TKI sequencing in EGFR mutation-positive NSCLC: A GioTag study US patient analysis

Bruce Feinberg, Balazs Halmos, Rasim Gucalp, Wenbo Tang, Barbara Moehring, Maximillian J. Hochmair

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Aim: To assess time-to-treatment failure (TTF) in US patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib-osimertinib treatment in the global, observational GioTag study. Patients & methods: Patients had EGFR T790M mutation-positive disease after first-line afatinib and subsequently received osimertinib. The primary outcome was TTF. Results: In 129 patients at US centers, median TTF was 28.4 months (90% CI: 27.0-34.1). Median overall survival was 47.6 months (90% CI: 35.5-51.5). Conclusion: Sequential afatinib-osimertinib in this US-treated population was associated with long median TTF and represents an effective, evidence-based treatment option for US patients with EGFR mutation-positive NSCLC not presenting with active brain metastases or de novo T790M. Clinical Trial Registration: NCT03370770 (ClinicalTrials.gov.

Original languageEnglish (US)
Pages (from-to)1585-1595
Number of pages11
JournalFuture Oncology
Volume16
Issue number22
DOIs
StatePublished - Aug 2020

Keywords

  • NSCLC
  • afatinib
  • osimertinib
  • sequential treatment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Making the case for EGFR TKI sequencing in EGFR mutation-positive NSCLC: A GioTag study US patient analysis'. Together they form a unique fingerprint.

Cite this